[{"id":"8f9d762e-021e-4c20-8f14-6257969fc846","acronym":"","url":"https://clinicaltrials.gov/study/NCT05632939","created_at":"2022-12-01T15:57:05.783Z","updated_at":"2024-07-02T16:35:55.253Z","phase":"Phase 1/2","brief_title":"ASKB589 in Combination With CAPOX and Sintilimab in Patients With Advanced, and Unresectable G/GEJ Cancer.","source_id_and_acronym":"NCT05632939","lead_sponsor":"AskGene Pharma, Inc.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • capecitabine • oxaliplatin • ASKB589"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 02/10/2023","start_date":" 02/10/2023","primary_txt":" Primary completion: 02/10/2025","primary_completion_date":" 02/10/2025","study_txt":" Completion: 02/10/2026","study_completion_date":" 02/10/2026","last_update_posted":"2023-02-17"},{"id":"1a820df7-ed63-4b53-befa-97ea8dbdf065","acronym":"","url":"https://clinicaltrials.gov/study/NCT04632108","created_at":"2021-01-19T20:36:42.292Z","updated_at":"2024-07-02T16:35:55.308Z","phase":"Phase 1/2","brief_title":"A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04632108","lead_sponsor":"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ASKB589"],"overall_status":"Recruiting","enrollment":" Enrollment 214","initiation":"Initiation: 01/28/2021","start_date":" 01/28/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-02-16"}]